Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Musculoskeletal  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Bone Metastases Clinical Trials

A listing of Bone Metastases medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (11) clinical trials

Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients

Most men with fatal prostate cancer develop bone metastases and bone is often the dominant or the only site of metastatic disease. Bone metastases are an important cause of morbidity since they are associated with skeletal related events (SREs) including pathologic fractures, spinal cord compression, and need for surgery or ...

Phase

The Combination Therapy With Ra-223 and Enzalutamide

This study is to evaluate preliminary efficacy of Ra-223 in combination with Enzalutamide in progressive CRPC patients with bone metastasis

Phase

Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer

The purpose of this Phase II single-arm study is to evaluate the efficacy of Radium-223 in treating bone lesions from differentiated thyroid cancer that are I-131 refractory. Based on the results of the phase III trial, the protocol using an injection of Radium-223 activity of 50 kBq/kg b.w. given 6 ...

Phase

A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases

The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus docetaxel and zoledronic versus docetaxel and zoledronic alone as second line treatment for advanced non-squamous non-small cell lung cancer with bone metastases.

Phase

Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases ( -RT)

This is an international, multi-center, open-label, prospective, phase II study designed to assess the efficacy of radiation therapy in combination with Radium-223 dichloride in patients diagnosed with CRPC and oligo metastases bone disease. All patients enrolled in this study will have signed an informed consent form (ICF) and will adhere ...

Phase

Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)

Highly selective irradiation requires accurate target definition by high-resolution three-dimensional imaging. Co-registration of FDG-PET and high-resolution CT might be the imaging modality of choice. This choice might target radiation therapy precisely to the intra-osseous volume that is responsible for pain and to spare selectively healthy bone in the vicinity of ...

Phase

Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer

OBJECTIVES: Primary - Measure the efficacy of morphine sulfate at 8 weeks after radiofrequency ablation (RFA) of bone metastases. Secondary - Assess minimum and average pain and analyze use of morphine sulfate before and after RFA. - Determine disease progression by CT scan of bone. - Evaluate the percentage of ...

Phase

Concurrent Xeloda and Radiotherapy for Bone Metastases

Hypothesis: Radiosensitization using Xeloda should improve the rate of complete pain relief. Primary Objective: - To determine the frequency of pain relief for the proposed regimen. Secondary Objective(s): - To determine the duration of pain relief and narcotic relief for the proposed regimen. - To determine the frequency of narcotic ...

Phase

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

This is a multicenter, randomized, double blind, Phase II study. Participants eligible for this study have metastatic urothelial cancer and bone metastases and are planned to receive 4-6 cycles of a standard of care platinum-doublet regimen. In a double blind manner, 50 participants will be randomized in a 1:1 ratio ...

Phase

Denosumab in Treating Patients With ER and/or PR Positive HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

PRIMARY OBJECTIVES: I. To assess the effect of denosumab in Her2/neu negative ER+ and/or PR+ metastatic breast cancer patients who are in partial response (PR) or stable disease (SD) after starting systemic therapy with bone metastases and >= 5 circulating tumor cells (CTCs) by measuring the fraction of patients with ...

Phase